CX Institutional’s Kyntra Bio KYNB Stock Holding History

CX Institutional’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4	Closed	-$5K	–	793
2018 Q4	$5K	Buy	+4	New	+$4.5K	﹤0.01%	394

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CX Institutional's KYNB Position: Q1 2019 in Review

CX Institutional sold out of Kyntra Bio (KYNB) in Q1 2019, closing a stake of 4 shares — an estimated $5K sold.

CX Institutional first reported a position in KYNB in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 225 funds tracked by Wall St. Rank hold KYNB as of Q1 2019.

CX Institutional reported no remaining Kyntra Bio position as of Q1 2019 after selling out during the quarter.
CX Institutional sold 4 Kyntra Bio shares in Q1 2019, an estimated $5K.
CX Institutional first reported a position in Kyntra Bio in Q4 2018 and held it in 1 quarter.
CX Institutional's Kyntra Bio position peaked at $5K in Q4 2018.
225 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2019.

Based on CX Institutional's 13F filing for Q1 2019, filed 3 Apr 2019.